Clinical Oncology (Medical Treatment, Radiotherapy) and Precision Medicine

All Items

• Clinical trials in older patients with cancer – typical challenges, possible solutions, and a paradigm of study design in breast cancer

  Peeter Karihtala, Aglaia Schiza, Elena Fountzilas, Jürgen Geisler, Icro Meattini, Emanuela Risi, Laura Biganzoli, Antonios Valachis

  441-447

• Application of comprehensive molecular genetic profiling in precision cancer medicine, Hungarian experiences

  Erika Tóth, Zsófia Kürönya, Edina Soós, Tamás Pintér, Henriett Butz, Zsolt Horváth, Erzsébet Csernák, Vince Kornél Grolmusz, Judit Székely, Tamás Straussz, József Lövey, Levenete Jánvári, László Báthory-Fülöp, Péter Nagy, Csaba Polgár, Attila Patócs

  433-440

• The French multicentric molecular analysis platforms and personalized medicine trials MOST, MOST Plus and MEGAMOST

  Loic Verlingue, Marine Desevre, Marie Polito, Gwenaelle Garin, Christine Rodriguez, Wang Qing, Olivier Tredan, David Perol, Isabelle Ray-Coquard, Sylvie Chabaud, Jean Yves Blay

  411-417

• IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results

  Katarina Puco, Gro Live Fagereng, Sigmund Brabrand, Pitt Niehusmann, Egil Støre Blix, Eli Sihn Samdal Steinskog, Åse Haug, Cecilie Fredvik Torkildsen, Irja Alida Oppedal, Sebastian Meltzer, Åsmund Flobak, Kajsa Anna Margareta Johansson, Line Bjørge, Geir Olav Hjortland, Astrid Dalhaug, Jo-Åsmund Lund, Bjørnar Gilje, Marte Grønlie Cameron, Randi Hovland, Ragnhild S. Falk, Sigbjørn Smeland, Hege Elisabeth Giercksky Russnes, Kjetil Taskén, Åslaug Helland

  379-384

• PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe

  Kjetil Taskén , Soemeya F. Haj Mohammad, Gro Live Fagereng, Ragnhild Sørum Falk, Åslaug Helland, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Katarina Steen Carlsson, Bettina Ryll, Katriina Jalkanen, Anders Edsjö, Hege G. Russnes, Ulrik Lassen, Ebba Hallersjö Hult, Iwona Lugowska, Jean-Yves Blay, Loic Verlingue, Edvard Abel, Maeve A. Lowery, Matthew G. Krebs, Kristoffer Staal Rohrberg, Kristiina Ojamaa, Julio Oliveira, Henk M.W. Verheul, Emile E. Voest, Hans Gelderblom

  385-391

• Desmoplastic non-infantile ganglioglioma mimicking diffuse leptomeningeal glioneuronal tumor: precision diagnostics and therapeutic implications

  Pitt Niehusmann, Henning Leske, Vigdis Nygaard, Hege G. Russnes, Sen Zhao, Anna Latysheva, Ulrikke Straume Wiig, Birute Stankuniene, Aina Ulvmoen

  392-394

• The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP)

  Soemeya F. Haj Mohammad, Hans J.L. Timmer, Laurien J. Zeverijn, Birgit S. Geurts, Ilse A.C. Spiekman, Karlijn Verkerk, Florentine A.J. Verbeek, Henk M.W. Verheul, Emile E. Voest, Hans Gelderblom

  368-372

• A national precision cancer medicine implementation initiative for Finland

  Katriina J. Jalkanen, Erika Alanne, Sanna Iivanainen, Okko-Sakari Kääriäinen, Minna Tanner, Annika Auranen, Jussi Koivunen, Timo K. Nykopp, Pia Vihinen, Mika Mustonen

  395-397

• Treatment of vulvar cancer recurrence with electrochemotherapy: a case-control study

  Gregor Vivod, Masa Omerzel, Nina Kovacevic, Gorana Gasljevic, Ines Cilensek, Gregor Sersa, Maja Cemazar, Sebastjan Merlo

  351-357
• 

  Implementation of perioperative FLOT compared to ECX/EOX chemotherapy regimens in resectable esophagogastric adenocarcinomas: an analysis of real-world data

  Kristian Egebjerg, Tobias Sørup Andersen, Lene Bæksgaard, Rajendra Garbyal, Mette Siemsen, Michael Achiam, Paul Morten Mau-Sørensen

  322-329

• Discontinuation of imatinib in patients with oligometastatic gastrointestinal stromal tumour who are in complete radiological remission: a prospective multicentre phase II study

  Ivar Hompland, KJetil Boye, Anne Marit Wiedswang, Andri Papakonstantinou, Bård Røsok, Heikki Joensuu, Øyvind Bruland

  288-293

• Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice

  Aino Rajamaki, Marc Sorigue, Roosa E.I. Prusila, Milla E.L. Kuusisto, Hanne Kuitunen, Esa Jantunen, Santiago Mercadal, Taina Turpeenniemi-Hujanen, Juan-Manuel Sancho, Kaisa Sunela, Outi Kuittinen

  267-272

• Incidence and survival of primary metastatic breast cancer in Denmark; implication of breast cancer screening, classification, and staging practice

  Tobias Berg, Maj-Britt Jensen, Maria Rossing, Christian T. Axelsen, Iben Kümler, Lise Søndergaard, Marianne Vogsen, Ann S. Knoop, Bent Ejlertsen

  277-287

• Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study)

  Sampsa Kinos, Helga Hagman, Päivi Halonen, Leena-Maija Soveri, Mary O'Reilly, Per Pfeiffer, Jan-Erik Frödin, Halfdan Sorbye, Eetu Heervä, Gabor Liposits, Raija Kallio, Annika Ålgars, Raija Ristamäki, Tapio Salminen, Maarit Bärlund, Carl-Henrik Shah, Ray McDermott, Rebecka Röckert, Petra Flygare, Johannes Kwakman, Arco Teske, Cornelis Punt, Bengt Glimelius, Pia Österlund

  248-258

• Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study

  Rosalba Miceli, Hanna Eriksson, Giuseppe Lo Russo, Salvatore Alfieri, Maria Moksnes Bjaanæs, Filippo Pietrantonio, Loris De Cecco, Arsela Prelaj, Claudia Proto, Johan Franzén, Deirdre McDonnell, José Javier Berenguer Pina, Teresa Beninato, Laura Mazzeo, Patrizia Giannatempo, Elena Verzoni, John Crown, Åslaug Helland, Alexander Eustace

  213-219

• Primary splenic angiosarcoma: a case series of a rare oncological entity and diagnostic challenge

  Iris Dirven, Philippe Leclercq, Lionel D'Hondt, Valentine Delmotte, Pierre Lefesvre, Hendrik Reynaert, Frederik Vandenbroucke, Magali Surmont

  192-197

• Is the risk of ischemic heart disease in women after radiotherapy for breast cancer nowadays still (linearly) associated with the mean heart dose?

  Henk Struikmans, Anna Petoukhova, Joop H.M. Schreur, Mirjam E. Mast, Philip M. Poortmans

  175-178

• Area-based disparities in non-small-cell lung cancer survival

  Nelly-Maria Paakkola, Antti Jekunen, Eero Sihvo, Mikael Johansson, Heidi Andersén

  146-153

• Implementing MyChoice® CDx HRD testing for the Nordics: lessons from 2021 to 2023

  Lea Milling Korsholm, Verena Broecker, Mansoor Raza Mirza, Maria Rossing

  70-75

• KIDNEY-PAGER: analysis of circulating tumor DNA as a biomarker in renal cancer – an observational trial. Study protocol

  Laura Iisager, Johanne Ahrenfeldt, Anna Krarup Keller, Tommy Kjærgaard Nielsen, Niels Fristrup, Iben Lyskjær

  51-55

• Carl Blomqvist, Nordic network builder in oncology (1951–2023) †

  Micaela Hernberg, Johanna Mattson, Mikko Tenhunen, Jonas Bergh, Johan Ahlgren, Lars Holmberg, Malin Sund, Mef Nilbert

  3